CSIMarket
 
Eli Lilly And Company  (NYSE: LLY)
Other Ticker:  
 
 
Price: $738.2100 $-50.88 -6.448%
Day's High: $768.27 Week Perf: -10.62 %
Day's Low: $ 734.70 30 Day Perf: -19.12 %
Volume (M): 5,299 52 Wk High: $ 972.53
Volume (M$): $ 3,912,070 52 Wk Avg: $840.61
Open: $762.11 52 Wk Low: $711.40



 Market Capitalization (Millions $) 667,604
 Shares Outstanding (Millions) 904
 Employees 43,000
 Revenues (TTM) (Millions $) 45,043
 Net Income (TTM) (Millions $) 10,590
 Cash Flow (TTM) (Millions $) 450
 Capital Exp. (TTM) (Millions $) 5,058

Eli Lilly And Company
Company Profile: Eli Lilly and Company

Overview
Eli Lilly and Company is a global pharmaceutical firm committed to the discovery, development, manufacturing, and sale of pharmaceutical products. The company operates in a single significant business segment'pharmaceuticals'while its animal health division, although operational, does not materially impact its financial statements. Eli Lilly manufactures and distributes its products through various owned and leased facilities located in the United States, Puerto Rico, and 17 other countries, with sales across approximately 140 countries worldwide.

Research and Development
Eli Lillys success is largely driven by its ability to innovate and discover new pharmaceutical products, with a primary focus on preventing and treating human diseases. The company invests substantial resources in research aimed at developing therapeutics across various therapeutic areas, including oncology, neuroscience, diabetes care, and endocrinology. Eli Lilly also conducts research to develop animal health products, enhancing the efficiency of animal food production.

Distribution and Marketing
In the United States, Eli Lilly distributes its pharmaceutical products primarily through independent wholesale distributors, including major players such as AmerisourceBergen Corporation, Cardinal Health, Inc. and McKesson Corporation. The direct sales to the U.S. government and other manufacturers constitute a minor portion of total sales.

The companys marketing approach ensures that medical information and products are readily available to healthcare professionals, including physicians, pharmacies, and hospitals. A dedicated sales force employs various promotional strategies, including sales representative visits, advertisements in medical journals, the distribution of product samples, and participation in medical conferences.

Eli Lilly also engages in direct-to-consumer advertising for certain products, supported by comprehensive online resources that provide information about its major offerings.

Key Customer Segments
Large purchasers such as managed-care organizations, governmental bodies, and long-term care institutions represent a significant segment of Eli Lillys customer base in the U.S. The company has developed specialized sales teams to address the unique needs of these groups, often providing discounts or rebate arrangements to improve market access.

International Operations
Globally, Eli Lillys promotional activities predominantly rely on sales representatives, with variations in distribution patterns based on regional market dynamics. While neuroscience products form the largest category of total international sales, the company adapts its strategies to accommodate the specific requirements of each market.

Raw Materials and Supply Chain
The raw materials required for manufacturing Eli Lilly products are generally sourced from multiple suppliers, with certain key materials obtained from single sources. The company collaborates with third-party manufacturers for the production of specific pharmaceuticals, and any disruption in material supply could temporarily affect product availability until alternative sources or processes could be established.

Competition
Eli Lilly operates in a highly competitive pharmaceutical landscape, facing rivalry from both established companies and generic manufacturers. Important competitive factors include drug efficacy, safety, pricing, service, and effective marketing and research. As product exclusivity ends, Eli Lillys branded pharmaceuticals confront intensified price competition from generic alternatives. Moreover, in certain international markets where patent protections are weak or non-existent, competition from generic versions of its products becomes even more pronounced.

Conclusion
Eli Lilly and Company remains at the forefront of pharmaceutical innovation, focusing on improving patient outcomes through effective treatments. With a broad global reach and a strong commitment to research and development, Eli Lilly continues to strive to meet the evolving needs of healthcare professionals and patients worldwide.


   Company Address: Lilly Corporate Center Indianapolis 46285 IN
   Company Phone Number: 276-2000   Stock Exchange / Ticker: NYSE LLY


Customers Net Income grew by LLY's Customers Net Profit Margin grew to

36.3 %

2.41 %

• Customers Performance • Customers Expend. • Customers Efficiency • List of Customers


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ABBV   -10.77%    
BMY   -9.33%    
JNJ   -7.6%    
MRK   -9.24%    
PFE   -9.35%    
SNY   -6.27%    
• View Complete Report
   



Contract

Organovo Sells FXR Program to Eli Lilly Amidst Eli Lillys Robust Financial Performance,

Published Tue, Mar 25 2025 5:33 PM UTC

Organovo Completes Strategic Sale of FXR Program to Eli Lilly Amid Impressive Financial Growth In a notable strategic transaction in the biotechnology sector, San Diego-based Organovo Holdings, Inc. (Nasdaq: ONVO) has finalized the sale of its FXR program, which includes the leading product FXR314, to pharmaceutical giant Eli Lilly and Company (NYSE: LLY). This move, complet...

Merger and Acquisition

Organovo Capitalizes on Strategic Asset Sale: FXR Program Acquired by Eli Lilly in Major Biotechnology Transaction

Published Tue, Mar 25 2025 3:25 PM UTC

Breaking News: Organovo Holdings Completes Strategic Sale of FXR Program to Eli LillySAN DIEGO, March 25, 2025 ? Organovo Holdings, Inc. (Nasdaq: ONVO), a pioneering biotechnology firm dedicated to innovative treatments for inflammatory bowel disease (IBD), announced today the successful completion of a significant asset sale of its FXR program, which includes the promising ...

Business Update

Radionetics Oncology Enters Strategic Agreement with Eli Lilly Boosting Cancer Treatment Innovations

Published Mon, Jul 8 2024 12:47 PM UTC

GordonMD Global Investments, the prominent investment firm, has announced that its portfolio company, Radionetics Oncology, has entered into a strategic agreement with Eli Lilly and Company, a global pharmaceutical giant. Radionetics Oncology is well-known for its groundbreaking work in developing targeted radiopharmaceuticals for cancer treatment. This collaboration is set ...

Stocks on the Move

Eli Lilly and Company A Rising Star in the Pharmaceutical Industry

Published Mon, Jul 1 2024 4:20 PM UTC

In the competitive world of pharmaceuticals, finding a company that showcases impressive growth potential while maintaining financial stability is a key for investors. Eli Lilly and Company (NYSE:LLY) has recently emerged as an attractive stock option, catching the attention of billionaire investor Ray Dalio. This article delves into the performance and prospects of Eli Lil...

Stocks on the Move

Eli Lilly and Co. has been making headlines with positive developments, collaborations, and stock recommendations.

Published Fri, Jun 28 2024 2:24 PM UTC

In recent years, Eli Lilly and Co. (NYSE: LLY) has been at the forefront of innovation, with several noteworthy developments and collaborations in the pharmaceutical industry. However, while the company s stocks have shown promise, its suppliers revenues have declined. This article aims to provide a balanced analysis of recent events surrounding Eli Lilly and Co., shedding ...







Eli Lilly's Segments
U S    68.31 % of total Revenue
Outside U S    31.69 % of total Revenue
Cardiometabolic Health    64.75 % of total Revenue
Cardiometabolic Health U S    48.23 % of total Revenue
Cardiometabolic Health Outside U S    16.52 % of total Revenue
Mounjaro    27.21 % of total Revenue
Mounjaro U S    20.85 % of total Revenue
Mounjaro Outside U S    6.36 % of total Revenue
Trulicity    11.38 % of total Revenue
Trulicity U S    8.18 % of total Revenue
Trulicity Outside U S    3.2 % of total Revenue
Zepbound    11 % of total Revenue
Zepbound U S    11 % of total Revenue
Jardiance    6 % of total Revenue
Jardiance U S    2.94 % of total Revenue
Jardiance Outside U S    3.06 % of total Revenue
Humalog    4.67 % of total Revenue
Humalog U S    2.83 % of total Revenue
Humalog Outside U S    1.84 % of total Revenue
Humulin    1.81 % of total Revenue
Humulin U S    1.31 % of total Revenue
Humulin Outside U S    0.5 % of total Revenue
Basaglar    1.41 % of total Revenue
Basaglar U S    0.75 % of total Revenue
Basaglar Outside U S    0.67 % of total Revenue
Baqsimi    0.12 % of total Revenue
Baqsimi U S    0.07 % of total Revenue
Baqsimi Outside U S    0.04 % of total Revenue
Other cardiometabolic health    1.15 % of total Revenue
Other cardiometabolic health U S    0.31 % of total Revenue
Other cardiometabolic health Outside U S    0.84 % of total Revenue
Oncology    19.51 % of total Revenue
Oncology U S    11.31 % of total Revenue
Oncology Outside U S    8.2 % of total Revenue
Verzenio    11.97 % of total Revenue
Verzenio U S    7.68 % of total Revenue
Verzenio Outside U S    4.29 % of total Revenue
Cyramza    2.06 % of total Revenue
Cyramza U S    0.93 % of total Revenue
Cyramza Outside U S    1.13 % of total Revenue
Erbitux    1.33 % of total Revenue
Erbitux U S    1.16 % of total Revenue
Erbitux Outside U S    0.16 % of total Revenue
Tyvyt    1.31 % of total Revenue
Tyvyt Outside U S    1.31 % of total Revenue
Other oncology    2.84 % of total Revenue
Other oncology U S    1.54 % of total Revenue
Other oncology Outside U S    1.3 % of total Revenue
Immunology    10.37 % of total Revenue
Immunology U S    6.07 % of total Revenue
Immunology Outside U S    4.3 % of total Revenue
Taltz    7.69 % of total Revenue
Taltz U S    5.25 % of total Revenue
Taltz Outside U S    2.44 % of total Revenue
Olumiant    2.19 % of total Revenue
Olumiant U S    0.6 % of total Revenue
Olumiant Outside U S    1.59 % of total Revenue
Other immunology    0.48 % of total Revenue
Other immunology U S    0.22 % of total Revenue
Other immunology Outside U S    0.27 % of total Revenue
Neuroscience    3.08 % of total Revenue
Neuroscience U S    1.76 % of total Revenue
Neuroscience Outside U S    1.32 % of total Revenue
Emgality    1.77 % of total Revenue
Emgality U S    1.24 % of total Revenue
Emgality Outside U S    0.54 % of total Revenue
Zyprexa    0.28 % of total Revenue
Zyprexa U S    0.02 % of total Revenue
Zyprexa Outside U S    0.26 % of total Revenue
Other neuroscience    1.02 % of total Revenue
Other neuroscience U S    0.51 % of total Revenue
Other neuroscience Outside U S    0.52 % of total Revenue
Other    0.47 % of total Revenue
Other U S    0.27 % of total Revenue
Other Outside U S    0.19 % of total Revenue
Forteo    1.03 % of total Revenue
Forteo U S    0.63 % of total Revenue
Forteo Outside U S    0.41 % of total Revenue
Cialis    0.8 % of total Revenue
Cialis U S    0.04 % of total Revenue
Cialis Outside U S    0.76 % of total Revenue
Europe    14.23 % of total Revenue
Japan    3.75 % of total Revenue
China    4.02 % of total Revenue
Other foreign countries    9.69 % of total Revenue





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright � 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com